Nectar builds a vertically integrated allergy care platform combining a hybrid virtual and physical clinic model, a compounding pharmacy, lab testing, and an allergist physician network. The company offers custom-formulated sublingual drops delivered to patients’ homes using patent-pending protocols for Sublingual Allergen Immunotherapy. Led by CEO Kenneth Chahine, Nectar aims to align incentives across care delivery to improve patient experience and outcomes. The company plans to use its new capital in 2023 to scale its virtual care platform nationwide, open its first physical location to comprehensively treat allergies, and initiate clinical studies. Financially, the company has raised over $24M in equity to date, including its recent Series A.

Total raised

$17M

Funding rounds

1

Latest round

Series A

Latest activity

Dec 2022